Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
8Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
enGene Therapeutics Inc. (ENGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
21Total relationships
4Distinct source URLs
13High confidence
0.800Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
the Borrower, Hercules Capital, Inc., as agent and lender ("Hercules") and the several banks and other financial institutions or entities (with Hercules, the "Lenders") from time to time parties thereto
Reciprocal relationship from HTGC graph: Reciprocal relationship from ENGN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ENGN graph: the Borrower, Hercules Capital, Inc…
CDMOS
CDMOS
90%
The Company enters into contracts in the normal course of business with CROs, CDMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufac…
CROS
CROS
90%
The Company enters into contracts in the normal course of business with CROs, CDMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufac…
INDEPENDENT-CMOS
INDEPENDENT-CMOS
90%
We currently rely on our commercial relationships with independent CMOs to supply our clinical trials.
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
90%
The Company may sell its common shares, without par value (the “Common Shares”), from time to time through Leerink Partners.
THIRD-PARTY-VENDORS
THIRD-PARTY-VENDORS
90%
The Company enters into contracts in the normal course of business with CROs, CDMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufac…
JEFFERIES-LLC
JEFFERIES-LLC
85%
the Company terminated the Open Market Sale Agreement SM , dated as of December 20, 2024 (the “Prior Sales Agreement”), that the Company had previously entered into with Jefferies LLC, as sales agent.
SELECTED-QUALIFIED-CMOS
SELECTED-QUALIFIED-CMOS
85%
We plan to enter into long term commercial supply agreements with selected qualified CMOs to supply detalimogene in the event that we are granted marketing approval in the United States.
Reciprocal relationship from HTGC graph: Reciprocal relationship from ENGN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ENGN graph: months ended January 31, 2025 to $8…
months ended January 31, 2025 to $8.9 million for the three months ended January 31, 2026. This increase was primarily attributable to the following: • a $1.5 million increase in personnel-related ex…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
months ended January 31, 2025 to $8.9 million for the three months ended January 31, 2026. This increase was primarily attributable to the following: • a $1.5 million increase in personnel-related ex…
FORBION-EUROPEAN-ACQUISITION-COMPANY
FORBION-EUROPEAN-ACQUISITION-COMPANY
62%
patients with high-risk BCG-naïve NMIBC with CIS (Cohort 2a, with 30 enrolled patients as of November 11, 2025) and patients with high-risk BCG-exposed NMIBC with CIS (Cohort 2b, with 45 enrolled pat…
FORBION-EUROPEAN-ACQUISITION-CORPORATION
FORBION-EUROPEAN-ACQUISITION-CORPORATION
62%
months ended January 31, 2025 to $8.9 million for the three months ended January 31, 2026. This increase was primarily attributable to the following: • a $1.5 million increase in personnel-related ex…
JEFFERIES-LLC-LEERINK-PARTNERS-LLC
JEFFERIES-LLC-LEERINK-PARTNERS-LLC
62%
. The effective interest rate of the 2026 Term Loan was 12.17 % as of January 31, 2026. At the Company's option, the Company may elect to prepay all, but not less than all, of the outstanding term lo…
NATURE-TECHNOLOGY-CORPORATION
NATURE-TECHNOLOGY-CORPORATION
62%
est senior to any current and future debts and to any security interest in all of our right, title, and interest in, to and under all of our property and other assets, subject to limited exceptions i…
WELLS-FARGO-SECURITIES-LLC
WELLS-FARGO-SECURITIES-LLC
62%
. The effective interest rate of the 2026 Term Loan was 12.17 % as of January 31, 2026. At the Company's option, the Company may elect to prepay all, but not less than all, of the outstanding term lo…
enGene Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ENGN-DEBT-9302
Warrants outstanding: 11.5
90%
xbrl warrant detail from xbrl 2024-10-31.
ENGN-DEBT-9303
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-10-31.
ENGN-DEBT
Debt stack $33.5M
90%
Market cache reports total debt of $33.5M.
enGene Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for enGene Therapeutics Inc..
enGene Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
ENGN-OWNER-FCPM-III-SERVICES-B-V
FCPM III Services B.V.
90%
13F overlay lists FCPM III Services B.V. as top holder; 10 tracked holders.
enGene Therapeutics Inc. Extended Supply Chain Network
